RxDoctor Payments Data

Prashant Sharma, MD

Gastroenterology · Carrollton, GANPI 1902059314

Payments from drug & device makers

$9,525in general payments, 2019–2025

Across 443 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$2K
  • Boston Scientific$660
  • Phathom Pharmaceuticals, Inc.$584
  • Sanofi$465
  • Pfizer$414
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$2262%
  • Food & beverage$9,29398%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,525 in reported general payments places this provider in the 75th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$131,600
Medicare patients
434
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase71$215,920
RinvoqUpadacitinib16$145,639
InflectraInfliximab-Dyyb11$143,418
LinzessLinaclotide134$97,429
ZenpepLipase/Protease/Amylase20$73,042
RemicadeInfliximab12$54,968
XifaxanRifaximin14$38,035
VoqueznaVonoprazan Fumarate34$22,347
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates127$8,276
Mesalamine14$8,093
Pantoprazole Sodium1,054$8,042
Dexlansoprazole DrDexlansoprazole38$8,039
Sucralfate318$5,832
Colestipol Hcl85$5,614
Dicyclomine Hcl131$2,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Rinvoq, Linzess$1,813$458,989221 claims
PfizerInflectra$414$143,41811 claims
Aimmune Therapeutics, Inc.Zenpep$125$73,04220 claims
Johnson & JohnsonRemicade$354$54,96812 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,258$38,03514 claims
Phathom Pharmaceuticals, Inc.Voquezna$584$22,34734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →